GSK to buy RAPT Therapeutics for $2.2 billion-March 2024-www.financetom.com

GSK to buy RAPT Therapeutics for $2.2 billion

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

GSK to buy RAPT Therapeutics for $2.2 billion

Mar 11, 2026 1:00 AM

Jan 20 (Reuters) - ‌GSK said ‍on ⁠Tuesday ⁠that ‌it

would acquire ⁠U.S.-based ‍RAPT Therapeutics for $2.2

billion.

(Reporting ‍by Pushkala ‍Aripaka in Bengaluru; Editing by

Subhranshu ‍Sahu)

Previous page： Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 bln Next page： Prosperity Bancshares Q3 Earnings, Revenue Increase; Quarterly Dividend Raised

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 bln

Oct 23, 2024

Oct 23 (Reuters) - Merck ( MRK ) has acquired privately held Modifi Biosciences for up to $1.3 billion to gain access to its experimental DNA modification-enabled cancer therapeutics, Modifi said on Wednesday. ...

Prosperity Bancshares Q3 Earnings, Revenue Increase; Quarterly Dividend Raised

Oct 23, 2024

07:14 AM EDT, 10/23/2024 (MT Newswires) -- Prosperity Bancshares ( PB ) reported Q3 earnings Wednesday of $1.34 per diluted share, up from $1.20 a year earlier. Analysts polled by Capital IQ expected $1.31. Revenue for the quarter ended Sept. 30, expressed as the sum of net interest income and total non-interest income, was $302.8 million, up from $278.3 million...

Evercore's Q3 Adjusted Earnings, Revenue Increase

Oct 23, 2024

07:15 AM EDT, 10/23/2024 (MT Newswires) -- Evercore ( EVR ) reported Q3 adjusted earnings Wednesday of $2.04 per diluted share, up from $1.30 a year earlier. Analysts polled by Capital IQ expected $2. Revenue for the quarter ended Sept. 30 was $738.4 million, up from $574.4 million a year earlier. Analysts surveyed by Capital IQ expected $726 million. Price:...

TransUnion's Q3 Adjusted Earnings, Revenue Rise; Provides Q4 Outlook, Raises 2024 Guidance

Oct 23, 2024

07:12 AM EDT, 10/23/2024 (MT Newswires) -- TransUnion ( TRU ) reported Q3 adjusted earnings Wednesday of $1.04 per diluted share, up from $0.91 a year earlier. Analysts polled by Capital IQ expected $1.01. Revenue for the quarter ended Sept. 30 was $1.09 billion compared with $968.7 million a year earlier. Analysts surveyed by Capital IQ expected $1.06 billion. For...